Johnson & Johnson announced that it is starting the Phase 1 of first-in-human clinical trial of a preventive Ebola vaccine on Tuesday. The vaccine is developed at Janssen Pharmaceutical Companies and trial will be headed by the Oxford Vaccine Group.
By January's end, enrollment will be completed. First volunteers have already received the first vaccine dose. The vaccine uses a booster developed by Denmark's Bavarian Nordic. The Oxford Vaccine Group has asked 72 healthy adult volunteers from the Oxfordshire area to be part of the phase 1 trial.